诚达药业 (301201)
ChengDa Pharmaceuticals Co.,Ltd.
K-Line Chart
No K-line data
Stock Details
1. Key Indicators
- Total Shares(W): 15471.38
- Circulating A-Shares(W): 10854.43
- Earnings Per Share(RMB): 0.1107
- Net Assets Per Share(RMB): 13.7643
- Operating Revenue(W RMB): 28509.47
- Total Profit(W RMB): 1797.42
- Net Profit Attributable to Parent(W RMB): 1677.33
- Net Profit Growth Rate(%): -58.47
- Weighted Return on Equity(%): 0.7800
- Operating Cash Flow Per Share(RMB): 0.4300
- Undistributed Profit Per Share(RMB): 1.9304
- Capital Reserve Per Share(RMB): 10.9488
2. Main Business
The main business covers:
- Providing key pharmaceutical intermediates and API CDMO R&D and production services for multinational pharmaceutical companies and pharmaceutical R&D institutions.
- R&D, production, and sales of L-carnitine series products and APIs.
- R&D of stem cell drugs.
3. Company Basic Information
- Company Name: ChengDa Pharmaceuticals Co., Ltd.
- Listing Date: 2022-01-20
- Industry: Pharmaceutical Manufacturing
- Address: No. 36 Huanghe Road, Huimin Street, Jiashan County, Jiaxing City, Zhejiang Province, China.
- Website: www.chengdapharm.com
- Company Profile: The company was established as a joint-stock company in 2009 through the overall transformation of its predecessor. It is primarily engaged in pharmaceutical intermediate and API CDMO services, R&D, production, and sales of L-carnitine series products and APIs, and R&D of stem cell drugs.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Shenzhen Shengtai Investment Management Co., Ltd. - Shenzhen Qianhai Shengtai Investment Enterprise (Limited Partnership) | General Legal Person | 1100.69 | 10.14 |
| 2 | Jiashan Huicheng Equity Investment Partnership (Limited Partnership) | General Legal Person | 332.86 | 3.07 |
| 3 | Jiashan Hecheng Equity Investment Partnership (Limited Partnership) | General Legal Person | 263.20 | 2.42 |
| 4 | Shenzhen Jiuheng Investment Advisory Co., Ltd. | General Legal Person | 170.29 | 1.57 |
| 5 | Everbright Securities Asset Management - Industrial Bank - Everbright Securities Asset Management ChengDa Pharmaceuticals Employee Participation in ChiNext Strategic Placement Collective Asset Management Plan | Asset Management Plan | 145.27 | 1.34 |
5. Concept Sectors
- Immunotherapy
- CXO Concept
- Hepatitis Concept
- Innovative Drugs
- Synthetic Biology
- Margin Trading & Securities Lending
- Low-Profit Stock
- Below IPO Price
- Specialized, Refined, Distinctive, and Innovative Enterprises
Remarks
- Data update date: 2026-01-01
- Data source: Public Market Information